Skip to main content
. 2022 Jun 20;12:904315. doi: 10.3389/fonc.2022.904315

Figure 3.

Figure 3

Clinical application of the urine exosomal AMACR. The DCA indicates that urine AMACR has a higher net benefit across a threshold of 20%–50% probabilities for diagnosing PCa (A, C) and csPCa (B, D) in two cohorts. (E) Waterfall plot of the urine AMACR in relation to prostate biopsy results (n = 272). Red bar indicates the ISUP grade ≥2 tumors (GS ≥ 7); the blue one indicates the ISUP grade 1 tumors (GS = 6); the green one indicates the negative biopsies. Two horizontal lines represent the cutoff points of 9.8 at a sensitivity of 90% and 8.9 at a sensitivity of 95%.